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The first phase IIb safety and efficacy trial of a new tuberculosis vaccine since that for BCGwas completed in October 2012. BCG-
vaccinated South African infants were randomized to receive modified vaccinia virus Ankara, expressing theMycobacterium tu-
berculosis antigen 85A (MVA85A), or placebo. MVA85A did not significantly boost the protective effect of BCG. Cryopreserved
samples provide a unique opportunity for investigating the correlates of the risk of tuberculosis disease in this population. Due
to the limited amount of sample available from each infant, preliminary work was necessary to determine which assays and con-
ditions give the most useful information. Peripheral bloodmononuclear cells (PBMC) were stimulated with antigen 85A
(Ag85A) and purified protein derivative fromM. tuberculosis in an ex vivo gamma interferon (IFN-) enzyme-linked immu-
nosorbent spot assay (ELISpot) and a Ki67 proliferation assay. The effects of a 2-h or overnight rest of thawed PBMC on ELISpot
responses and cell populations were determined. Both the ELISpot and Ki67 assays detected differences between theMVA85A
and placebo groups, and the results correlated well. The cell numbers and ELISpot responses decreased significantly after an
overnight rest, and surface flow cytometry showed a significant loss of CD4 and CD8 T cells. Of the infants tested, 50% had a
positive ELISpot response to a single pool of flu, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) (FEC) peptides. This pilot
work has been essential in determining the assays and conditions to be used in the correlate study.Moving forward, PBMCwill be
rested for 2 h before assay setup. The ELISpot assay, performed in duplicate, will be selected over theKi67 assay, and furtherwork is
needed to evaluate the effect of high FEC responses on vaccine-induced immunity and susceptibility to tuberculosis disease.
Disease caused by Mycobacterium tuberculosis continues to be amajor global health problem. In 2012, there were 8.6 million
new cases of tuberculosis (TB) worldwide and 1.3 million people
died of the disease (1). Bacille Calmette-Guérin (BCG), the only
licensed TB vaccine, has variable efficacy, ranging from 0 to 80%,
depending on the geographical location and population (2). A
vaccine which is able to provide universal protection is urgently
needed. The lack of a known correlate of protection against disease
caused by infection with M. tuberculosis continues to be a major
obstacle for the TB vaccine field, making it difficult to select which
vaccines should progress to large-scale efficacy trials and to pre-
dict how successful those vaccines will be. Since 2002, more than a
dozen candidate vaccines have entered into clinical testing (3),
with the aim of boosting the efficacy of BCG or replacing it alto-
gether. Only a few of these candidate vaccines have progressed to
large-scale efficacy trials (3). The results of the most advanced of
these, a phase IIb safety and efficacy trial of modified vaccinia virus
Ankara, expressing the M. tuberculosis antigen 85A (MVA85A) in
BCG-vaccinated South African infants, were published in Febru-
ary 2013 (5). MVA85A did not significantly improve the efficacy
of BCG in this population, despite promising preclinical data
from animal models (69) and the induction of potent and du-
rable T cell responses in earlier phase I/IIa clinical trials (10 –13).
Although enhanced protection was not achieved in this popula-
tion, peripheral blood mononuclear cells (PBMC) stored pre- and
postvaccination provide a unique opportunity to investigate im-
munological differences between those infants who went on to
develop TB disease and those who did not. With limited PBMC
available to do this, careful planning was needed in order to select
the assays which give the most relevant and diverse information.
Prior work using the mycobacteria growth indicator tube (MGIT)
assay and gene expression analysis demonstrated that high-quality
data can be obtained using samples from the same population of
South African infants, and these two assays (our unpublished
data) will be included in the correlate analysis. The aim of this
work was to determine which other assays have utility for inclu-
sion. Here we describe some pilot work carried out to evaluate the
optimum time that thawed PBMC should be rested before setting
up immunological assays and compare antigen-specific responses
to antigen 85A (Ag85A) and purified protein derivative (PPD)
from M. tuberculosis in the gamma interferon (IFN-) enzyme-
linked immunosorbent spot assay (ELISpot) and the Ki67 prolif-
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eration assays. The utility of cell surface flow cytometry was also
evaluated. This process of assay selection and optimization, prior
to the processing of the valuable correlate samples, has relevance
for all trials of new vaccines, where the amount of sample available
for analysis will always be limited.
MATERIALS AND METHODS
Origin of samples. (i) Infant samples. Samples used in these pilot exper-
iments were cryopreserved PBMC from a double-blind, randomized, pla-
cebo-controlled phase IIb efficacy trial of the candidate TB vaccine,
MVA85A, in BCG-vaccinated, HIV-negative South African infants
(South African National Clinical Trials Register DOH-27-0109-2654,
ClinicalTrials.gov registration no. NCT00953927). Collection of these
trial samples was approved by the University of Cape Town Faculty of
Health Sciences Human Research Ethics Committee, the Oxford Univer-
sity Tropical Research Ethics Committee, and the Medicines Control
Council of South Africa. The samples used were selected from a subgroup
of infants on whom gene expression analysis had already been planned,
and the remainder were from those infants who were lost to follow-up.
FIG 1 Detection of antigen-specific responses in infants vaccinated with MVA85A. IFN- ELISpot responses (A and B) and percentages of proliferating CD4
Ki67 (C and D) and CD8 Ki67 (E and F) in PBMC after stimulation with a single pool of antigen 85A peptides (A, C, and E) and purified protein derivative
(PPD) from M. tuberculosis (B, D, and F). Red lines show median responses. Significant differences (Mann-Whitney test): *, P 0.05; **, P 0.01. n 10 to 27
per time point.
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They were not from cases (infants who went on to develop TB disease) nor
from matched controls.
(ii) Adult samples. Samples used in this study were cryopreserved
PBMC from BCG-vaccinated, United Kingdom adults, 28 days after
MVA85A vaccination (1  108 PFU) (ClinicalTrials.gov registration no.
NCT01194180).
Experimental design. Infants enrolled in this trial were 4 to 6 months
old and had received BCG (Danish 1331; Statens Serum Institute [SSI],
Denmark) within 7 days of birth. They were randomized to receive an
intradermal vaccination with either MVA85A (1  108 PFU) or placebo
(Candida skin test antigen) (5). Two subsets of samples were used in this
work. The first set consisted of PBMC taken at 0 to 7 days prevaccination
and 28 days postvaccination from 30 infants given MVA85A and 30 given
placebo. These samples were used for the Ki67 proliferation assay, to
quantify the proliferative potential of PBMC when stimulated with my-
cobacterial antigens, and for the ex vivo IFN- ELISpot assay, to quantify
the magnitude of the response to mycobacterial and nonmycobacterial
antigens. The ELISpot responses were also used to assess the intra-assay
variation, comparing responses across either duplicate or triplicate anti-
gen wells. The correlation between the two assays was investigated.
The second set of samples consisted of pre- and postvaccination
PBMC from 15 infants from each group (MVA85A andCandidaplacebo).
Due to the logistics of processing the large number of case and control
samples in the TB correlates of risk study, it is desirable to thaw and rest
PBMC overnight. This set of samples was used to compare ex vivo IFN-
ELISpot responses when PBMC were rested for 2 h or overnight. A subset
of 10 of these samples was used for cell surface flow cytometry to identify
cell populations and determine differences between a 2-h and an over-
night rest. As a comparison to the infant samples, PBMC from 12 adults at
28 days after MVA85A vaccination were subjected to the same thawing
and resting conditions and were used for cell surface flow cytometry and
IFN- ELISpot assays.
Cell thawing. Two vials of cryopreserved PBMC from each sample
were rapidly thawed in a 37°C water bath and transferred to a 15-ml
Falcon tube containing 10 ml R10 (RPMI medium, 10% fetal calf serum,
1% L-glutamine, 1% penicillin-streptomycin, 1% sodium pyruvate).
PBMC were pelleted, supernatants were discarded, and the samples were
resuspended in 10 ml R10 with 20l Benzonase (25 U/l) (Merck Chem-
icals Ltd.) and rested overnight at 37°C and 5% CO2. For the 2-h versus
overnight comparison, PBMC were split into equal volumes; one set was
rested for 2 h, and one set was rested overnight. PBMC were counted on a
Casy counter (Roche) and split into the appropriate volumes for each
assay. In some cases, there were inadequate numbers of cells to perform all
assays and use all conditions.
Ex vivo IFN- ELISpot assay. The ex vivo IFN- ELISpot assay was
performed on both subsets of samples, thawed PBMC from prevaccina-
tion and 28 days postvaccination as previously described (13). In a 96-well
ELISpot plate (Millipore), triplicate wells containing 3 105 PBMC were
stimulated with a single pool of Ag85A peptides, consisting of 66 15-mer
peptides, overlapping by 10 amino acids (2g/ml/peptide) (Peptide Pro-
tein Research), BCG from pooled SSI vaccine vials (2  105 CFU/ml),
purified protein derivative (PPD) from M. tuberculosis (20 g/ml) (SSI),
FEC, consisting of a single pool of flu, Epstein-Barr virus (EBV), and
cytomegalovirus (CMV) peptides (10 g/ml/peptide) (Peptide Protein
Research), and combined TB10.3 and TB10.4 peptides (10 g/ml/pep-
tide) (Peptide Protein Research). Phytohemagglutinin (PHA) (Sigma)
was used as a positive control, and unstimulated wells were used as a
measure of background IFN- production. The results are reported as
spot-forming cells (SFC) per million PBMC, calculated by subtracting the
mean of the unstimulated wells from the mean of triplicate antigen wells
and correcting for the numbers of PBMC in the wells. A response was
considered positive if the mean number of spots in the antigen well was at
least twice the mean of the unstimulated wells and at least 5 spots greater.
Ki67 proliferation assay. PBMC were counted and plated in 24-well
plates at 1 106 PBMC/1 ml R10. Plates were incubated for 6 days at 37°C
and 5% CO2 with either 2 g/ml PPD or 1 g/ml/peptide of a single pool
of antigen 85A peptides. Two wells of PBMC were left unstimulated in
R10. After 3 days, PHA was added to one of the unstimulated wells at 0.3
g/ml. Three days later, the cells were washed in phosphate-buffered
saline (PBS) and stained with amine-reactive viability dye (Live/Dead
fixable red dead cell stain; Invitrogen). Cells were then permeabilized
with Perm/Wash (BD Biosciences) and incubated with monoclonal
antibodies: anti-CD3-AF700, anti-CD4-PB, anti-Ki67-phycoerythrin
(PE) (BioLegend), and anti-CD8-allophycocyanin (APC)/AF750 (Beck-
man Coulter). Cells were then washed and acquired on a BD LSR II flow
cytometer (BD Biosciences, San Jose, CA). Data were analyzed using
FlowJo software (Tree Star Inc.). Dead cells were excluded from the anal-
ysis, while singlet CD3 T cells, CD3 CD4 T cells, and CD3 CD8 T
cells were included. Proliferating cells are presented as the percentage of
Ki67 T cells out of the total CD4 or CD8 T cells. Background (un-
stimulated) values were subtracted from all data.
Cell surface flow cytometry. PBMC were washed and stained with
Live/Dead fixable red dead cell stain (Invitrogen) followed by surface
staining with the following antibodies: anti-CD3-AF700, anti-CD4-PB,
anti-CD14-PE/Cy7, anti-CD16-AF488, anti-CD19-PE/Cy5, anti-CD25-
APC/Cy7, 	 T cell receptor (TCR)-APC, anti-cytotoxic-T-lymphocyte-as-
sociated antigen (CTLA)-PE (all from BioLegend), anti-CD8-efluorNC605,
and anti-CD127-efluorNC650 (eBioscience). Fluorescence minus one
(FMO) controls were used to identify boundaries of gates for CD25,
	TCR, CD127, and CTLA. Samples were acquired on a BD LSR II flow
cytometer. Results are presented as percentages of cells after gating out of
dead cells and doublets. CD4 and CD8 T cells were identified as CD3
cells, while CD14/ and CD16/ cells were identified as CD3 and
CD19 populations. CTLA and CD25CD27 populations were gated
on the CD4 cells.
Statistical analysis. Statistical analyses were performed using GraphPad
Prism and SPSS. The Mann-Whitney test was used to compare differences
between groups. The Wilcoxon matched-pairs signed-rank test was used
to compare responses after a 2-h or an overnight rest. Spearman’s rho was
used to determine correlations between the ELISpot and Ki67 prolifera-
tion assays. The intraclass correlation (ICC) with a two-way mixed-effects
TABLE 1 Correlations between percent CD4 Ki67 PBMC and IFN-
ELISpot responses in South African infants after vaccination with either
MVA85A or placebo (vaccination groups combined)
No. of days
postvaccination Antigen
Correlation coefficient
(Spearman’s rho) P
0 85A 0.202 NSa
0 PPD 0.528 0.002
28 85A 0.494 0.005
28 PPD 0.362 0.042
a NS, not significant.
TABLE 2 Intraclass correlation two-way mixed-effects model
comparing reliability between duplicate and triplicate wells in the ex
vivo IFN- ELISpot assay for 41 infant samples at baseline and D28
No. of days
postvaccination Antigen
ICC fora:
Wells 1
and 2
Wells 1
and 3
Wells 2
and 3
Wells 1, 2,
and 3
0 85A 0.594 0.641 0.655 0.719
0 PPD 0.931 0.923 0.921 0.949
0 BCG 0.926 0.925 0.936 0.952
28 85A 0.934 0.904 0.895 0.939
28 PPD 0.858 0.855 0.834 0.895
28 BCG 0.892 0.868 0.896 0.920
a Intraclass correlation (ICC) values: 0 to 0.2, poor; 0.3 to 0.4, fair; 0.4 to 0.6, good; 0.6
to 0.8, very good; and 0.8 to 1.0, excellent.
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model was used to assess the reproducibility between duplicate and trip-
licate wells in the IFN- ELISpot assay.
RESULTS
Ki67 proliferation assay results correlate with IFN- ELISpot
responses. Both the IFN- ELISpot and Ki67 assays detected sig-
nificant differences (P 0.001 and 0.03, respectively) between the
MVA85A and placebo groups at 28 days postvaccination in re-
sponse to stimulation with a single pool of antigen 85A peptides
(Fig. 1A and C). A significant difference between the baseline and
postvaccination responses in the MVA85A group was also de-
tected using the ELISpot assay (P 0.001) but was not detected in
the Ki67 assay, possibly due to the low number of samples avail-
able for this assay in the MVA85A group on day 0 (D0). Neither
assay detected any differences between groups or time points in
response to stimulation with PPD (Fig. 1B, D, and F). Significant
correlations were observed between the two assays for PPD re-
sponses at baseline and for both PPD and antigen 85A responses at
D28 (vaccination groups combined) (Table 1).
Intra-assay variation. The intraclass correlation (ICC) has
been reported as an improved measure of reliability for quantita-
tive data, where reliability is the reproducibility of a biological
measurement when it is repeated for the same study subject (14).
The ICC was used in this study to measure the reproducibility of
responses detected in replicate wells of the ELISpot assay. The ICC
improved as the magnitude of the detected IFN- ELISpot re-
sponse increased. ICC values for duplicate (all combinations) and
triplicate ELISpot wells indicated a good (ICC of 0.4 to 0.6) or very
good (ICC of 0.6 to 0.8) level of agreement for baseline responses
to antigen 85A and an excellent (ICC of 0.8 to 1.0) level of agree-
ment for all other antigens and time points (Table 2).
Cell counts are significantly lower overnight. PBMC were
counted on a Casy counter (Roche) after both the 2-h and over-
night rests (Fig. 2). Infant 2-h counts ranged from a total of 1.1
106 to 2.3 107 cells, with overnight counts ranging from a total of
1.4 106 to 2.5 107 cells. A significant reduction in the median
of the cell counts was observed, with counts of 7.7 106 and 6.9
106 for the 2-h and overnight rests, respectively (P  0.02) (Fig.
2A). The median adult PBMC count also showed a significant
reduction after the overnight rest (P 0.03) (Fig. 2B).
IFN- ELISpot responses are significantly lower after an
overnight rest. Figure 3 shows IFN- ELISpot responses after a
2-h and an overnight rest in both South African infants (groups
and time points combined) and United Kingdom adults. Re-
sponses to all five antigens tested in the infant population were
significantly lower after the overnight rest than after the 2-h rest
(Wilcoxon matched-pairs signed-rank test), despite equivalent
FIG 2 Cell viability is reduced in both adult and infant PBMC following overnight resting of cells. Infant (A) and adult (B) PBMC counts from a Casy counter
(Roche) after a 2-h or overnight rest. Lines show median and interquartile ranges. An asterisk indicates significant difference (P 0.05, Wilcoxon matched-pairs
signed rank test). Infants, n 56; adults, n 12.
FIG 3 IFN- ELISpot responses are reduced in both adult and infant PBMC following overnight resting of cells. Infant (pre- and postvaccination) (A) and adult
(postvaccination) (B) IFN- ELISpot responses after a 2-h or overnight rest. Red lines show median responses. Asterisks indicate significant differences
(Wilcoxon matched-pairs signed-rank test): *, P 0.05; **, P 0.01; ***, P 0.001. Infants, n 45 to 55; adults, n 12.
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numbers of PBMC in the ELISpot wells (Fig. 3A). The same was
true for the adult responses to the two antigens tested (Fig. 3B).
Loss of T cell populations is significant after an overnight
rest. Cell surface flow cytometry of 10 infant samples and 12 adult
samples showed a significant loss of viability overnight: a drop in
median viability of 93.9 to 92.0% in the infants (P  0.02) (Fig.
4A) and 94.3 to 89.2% in the adults (P  0.0005) (Fig. 4B). The
infant samples showed a significant loss of CD4 and CD8 T
FIG 4 Changes in lymphocyte and monocyte cell frequencies following overnight resting of cells. Infant (left) and adult (right) cell viability (A and B) and
percentages of total live CD4 (C and D), CD8 (E and F), and CD14 (G and H) cells after a 2-h or overnight rest. Lines show median values. Asterisks indicate
significant differences (Wilcoxon matched-pairs signed-rank test): *, P 0.05; ***, P 0.001. Infants, n 10; adults, n 12.
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cells after an overnight rest compared to that after a 2-h rest (P
0.01) (Fig. 4C and E) and a nonsignificant loss of CD14 mono-
cytes (Fig. 4G). In adults, a significant loss of CD8 and CD14
cells was observed (P  0.0005) (Fig. 4F and H). While the per-
centage of CD4 T cells significantly increased after an over-
night rest (P 0.0005) (Fig. 4D), the total number of CD4 T
cells did not.
Proportion of infants responding on IFN- ELISpot assay to
the FEC peptides was higher than expected. A single pool of FEC
peptides was included in the IFN- ELISpot assay for 30 infants.
After a 2-h rest of PBMC, 15 out of 30 infants had a positive
baseline or D28 response to these peptides, ranging from 27 to 783
SFC/million PBMC (median, 102 SFC/million PBMC) (Fig. 3A).
DISCUSSION
Here we have presented preliminary work on the down-selection
of assays and methods to be carried forward for investigating a
correlate of infection/risk of tuberculosis. This work used pre- and
postvaccination PBMC from a phase IIb efficacy trial of MVA85A
in BCG-vaccinated South African infants and showed that high-
quality data can be obtained from these cryopreserved samples.
Cell counts were variable, ranging from 1.1 to 23.3 million
(median, 7.7 million) for the 2-h rest and dropping significantly
overnight (median, 6.9 million). For most subjects, ample PBMC
were available to carry out the desired assays and conditions, sug-
gesting that it is worthwhile to plan to carry out multiple assays on
the case versus control samples, as, based on the cell counts in this
study, sample sizes will be large enough to make meaningful com-
parisons within each assay.
Both the ex vivo IFN- ELISpot and Ki67 proliferation assays
were able to detect differences in responses to antigen 85A be-
tween the placebo and MVA85A-vaccinated groups at 28 days
postvaccination. The ELISpot assay was also able to detect a dif-
ference between pre- and postvaccination responses to antigen
85A in the MVA85A group, which the Ki67 assay did not, possibly
due to a lower number of samples available for the Ki67 assay in
the MVA85A group at D0. The baseline responses to the PPD were
high due to all infants receiving BCG vaccination at birth, but
neither assay detected an increase in response to the PPD after
vaccination with MVA85A. This is in contrast to previous findings
in BCG-vaccinated United Kingdom adults and South African
adults, adolescents, and children, where we see significant in-
creases in responses to both Ag85A and PPD after vaccination
with MVA85A (11, 13, 15). The lack of an increase in PPD re-
sponses in infants may be due to the recency of the BCG vaccina-
tion and the fact that the corresponding Ag85A responses are
much lower than those we see in adults. There was good agree-
ment between the two assays, with significant correlations for PPD
responses at both the baseline and D28 and for antigen 85A re-
sponses at D28. The lack of correlation between the assays for
antigen 85A responses at baseline is probably due to the very low
responses detected at this time point. As a result of these findings
and due to the cell-intensive nature and length of time involved in
the Ki67 assay, we decided that the IFN- ELISpot assay would be
taken forward for the full correlate analysis and the Ki67 prolifer-
ation assay would not be performed on further samples from this
cohort.
Intra-assay variability was determined by looking at both du-
plicate and triplicate repeats in the ELISpot assay. Both numbers
of repeats produced excellent ICC values, suggesting that it is suf-
ficient to carry out the ELISpot with duplicate antigen wells, thus
saving a considerable number of valuable PBMC for use in other
assays.
Due to the logistical advantage, many trials of new vaccines
perform analyses on cryopreserved PBMC. However, the loss of
responses and therefore the loss of sensitivity of an assay with the
use of cryopreserved samples instead of fresh must be minimized.
Logistically, an overnight rest of thawed PBMC is desirable; how-
ever, a significant decrease in ELISpot responses for all of the an-
tigens tested for both infant and adult samples was observed when
PBMC were rested overnight compared with that when the same
samples were rested for only 2 h. Cell surface flow cytometry to
determine cell populations in the infant samples showed a signif-
icant loss of percentages of CD4 and CD8 T cells overnight,
which might explain the loss of antigen-specific IFN- production
in the ELISpot. A loss of monocytes, although not significant,
might also result in lower levels of antigen presentation. As a con-
sequence of this result, future assays will be set up after a rest of
only 2 h as this will minimize the loss of antigen-specific re-
sponses.
The inclusion of FEC, a nonmycobacterial pool of CD8
epitopes, in the ELISpot assay provided some interesting results.
While 50% of infants had no response to these peptides at either
the baseline or D28, the remaining 50% had positive responses,
with a median of 102 SFC/million PBMC. Infants in this trial were
4 to 6 months old when enrolled, so even at this very young age, a
noticeable proportion have immunological memories of exposure
to at least one of these viral pathogens. It will be of interest and
possibly of relevance to determine which of these pathogens the
infants are responding to. As a result, in the study of the correlate
samples, separate pools of EBV, CMV, and influenza peptides will
be included in the ELISpot panel.
An immune correlate analysis of the phase III HIV vaccine
efficacy trial with RV144 used 6 assays for the primary analysis,
selected on the basis of reproducibility, ability to detect postvac-
cine responses, and uniqueness of responses (16). The preliminary
work we have shown here has also demonstrated the importance
of selecting assays that are reproducible and sensitive enough to
detect differences between groups and, importantly, those that
measure different aspects of the immune response. This pilot
study has been essential in determining the optimal assays and
conditions to continue with for the TB immune correlate study.
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